Clinical trials: Prevention of Thromboembolic Events
Atrial Fibrillation
Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion
A study for patients with abnormal heart rhythm (atrial fibrillation) who need to undergo cardioversion (procedure to restore normal heart rhythm).
- Trial name
- X-VERT (NCT01674647)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Vitamin K antagonist (VKA)
- Where
- 178 sites in United States, Belgium and 15 more
- Volunteers
- 1,504 people
- Sponsor
- Bayer
Venous Thromboembolism
Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Hip Fracture Surgery
The primary objective was to compare the efficacy of once daily [q.d] subcutaneous [s.c.] injections of Semuloparin sodium (AVE5026) with q.d. s.c.
- Trial name
- SAVE-HIP2 (NCT00721760)
- Testing
- Enoxaparin sodium, Semuloparin sodium
- Where
- 25 sites in United States, Argentina and 23 more
- Volunteers
- 1,003 people
- Sponsor
- Sanofi
Circulatory Disease
Phase II Clinical Study of H001 Capsule in the Prevention of Venous Thromboembolism After Total Knee Arthroplasty
This study is a multicenter, randomized, open-label, positive-controlled Phase II clinical study to evaluate the efficacy and safety of H001 capsules in the prevention of venous thromboembolism (VTE) in subjects undergoing Total…
- Trial name
- NCT06963320
- Testing
- H001 Capsule 200mg-qd, Enoxaparin Sodium Injection, H001 Capsule 300mg-qd
- Where
- China
- Volunteers
- 320 people
- Sponsor
- Livzon Pharmaceutical Group Inc.
Neoplasms
A Study to Evaluate the Efficacy and Safety of Rivaroxaban Venous Thromboembolism (VTE) Prophylaxis in Ambulatory Cancer Participants
The purpose of this study is to demonstrate that rivaroxaban is superior to placebo for reducing the risk of the primary composite outcome as defined by objectively confirmed symptomatic lower extremity proximal deep vein…
- Trial name
- NCT02555878
- Testing
- Rivaroxaban
- Where
- 151 sites in United States, Belgium and 8 more
- Volunteers
- 841 people
- Sponsor
- Janssen Research & Development, LLC
Venous Thromboembolism
Explicit Assessment of Thromboembolic Risk and Prophylaxis for Medical Patients in Switzerland
Until now, no risk assessment model informing about the need of thromboprophylaxis in patients admitted for an acute medical event has been validated.
- Trial name
- NCT01277536
- Where
- 7 sites in Switzerland
- Volunteers
- 1,478 people
- Sponsor
- University Hospital, Geneva
Postoperative Thromboembolism
Effect of Tumescent Lidocaine on Platelet Function
The purpose of this study is to evaluate the effect of lidocaine, delivered into subcutaneous tissue for tumescent local anesthesia, on platelet activation following the tumescent liposuction.
- Trial name
- NCT01463280
- Testing
- tumescent lidocaine infiltration
- Where
- United States
- Volunteers
- 129 people, healthy volunteers welcome
- Sponsor
- Klein, Jeffrey A., M.D.
Patent Foramen Ovale, Cardiac Implantable Electronic Device
Patients With Patent Foramen Ovale and Endocardial Device Leads on Apixaban for Prevention of Paradoxical Emboli
Patients with a patent foramen ovale in the setting of endocardially placed cardiac implantable electronic devices such as pacemakers, defibrillators, or resynchronization therapies are likely at higher risk for paradoxical…
- Trial name
- PARADOX (NCT02378623)
- Testing
- Apixaban
- Where
- United States
- Sponsor
- Mayo Clinic
Postpartum, VTE Prophylaxis
Excretion of Rivaroxaban in Human Breast Milk
The purpose of this study is to investigate the distribution of rivaroxaban into human milk at both therapeutic and prophylactic doses, and over time with repeated dosing.
- Conditions
- Postpartum, VTE Prophylaxis, VTE (Venous Thromboembolism), Rivaroxaban
- Trial name
- LACT (NCT06831474)
- Testing
- Rivaroxaban 10 MG Oral Tablet, Rivaroxaban 20 MG Oral Tablet
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Thomas Jefferson University
Thromboembolism
Hip Fracture Study of GSK576428 (Fondaparinux Sodium)
This study is requested by PMDA to confirm the efficacy and the safety for HFS.
- Trial name
- NCT00320424
- Testing
- Fondaparinux
- Volunteers
- 48 people
- Sponsor
- GlaxoSmithKline
Venous Thromboembolism
Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Hip Fracture Surgery
The objective of this study is to evaluate the safety and efficacy of DU-176b compared with enoxaparin sodium for the prevention of venous thromboembolism in patients after elective hip fracture surgery.
- Trial name
- NCT01181141
- Testing
- DU-176b (edoxaban), Enoxaparin sodium 20mg
- Where
- Japan
- Volunteers
- 92 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Acute Coronary Syndrome, Venous Thrombosis
Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Sweden)
This prospective cohort study will provide information about: Characteristics of Rivaroxaban use in patients who are prescribed Rivaroxaban for the first time compared to patients who are prescribed standard of care for the first…
- Conditions
- Acute Coronary Syndrome, Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation
- Trial name
- NCT02468102
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Standard of care drugs
- Where
- Sweden
- Volunteers
- 99,999 people
- Sponsor
- Bayer
Venous Thromboembolism, Renal Impairment
Enoxaparin 20mg Versus 30mg Subcutaneously Once Daily in Elderly Patients With Impaired Renal Function
This is a clinical trial including non-surgical patients, 70 years of age or older, with renal impairment requiring pharmacological venous thromboembolism prevention during hospitalization.
- Trial name
- NCT03158792
- Testing
- Enoxaparin 20Mg/0.2mL Prefilled Syringe, Enoxaparin 60Mg/0.6Ml Inj Syringe 0.6Ml
- Where
- Lebanon
- Volunteers
- 32 people
- Sponsor
- Lebanese American University
Venous Thromboembolism
Bemiparin Versus Enoxaparin in the Prevention of Venous Thromboembolism Among ICU Patients
The purpose of this study is to compare two types of low-molecular-weight heparin, enoxaparin and bemiparin, as regards their efficacy and safety in venous thromboembolism prevention among intensive care unit patients.
- Trial name
- NCT02795065
- Testing
- Enoxaparin, Bemiparin
- Volunteers
- 100 people
- Sponsor
- Mohamed Sayed Mohamed Abbas
Thromboembolism, Venous Thromboembolism
Retrospective Study of Patients Who Were Treated With Fondaparinux Pre-, Peri- and/or Postpartum for Prophylaxis or Treatment of Venous Thromboembolism
The objective of this retrospective study is to gather information about how fondaparinux is used pre-, peri- and/or postpartum for both the prophylaxis and treatment of venous thromboembolism (VTE) in order to fill an…
- Trial name
- FondaPPP (NCT01004939)
- Testing
- fondaparinux
- Where
- 7 sites in Germany
- Volunteers
- 120 people
- Sponsor
- GlaxoSmithKline
Venous Thromboembolism
Title: Randomized Trial of an EHR Embedded Risk Calculator vs. Standard VTE Prophylaxis for Medical Patients
Venous thromboembolism (VTE) is a serious source of hospital morbidity and mortality. Chemoprophylaxis with heparin has been shown to reduce the occurrence of VTE, but it increases the risk of bleeding and it is uncomfortable to…
- Trial name
- NCT03243708
- Testing
- Risk calculator
- Where
- United States
- Volunteers
- 90,537 people
- Sponsor
- The Cleveland Clinic
Venous Thromboembolism, Thromboembolism
A Phase 2b Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty
The objective of this study is to compare the efficacy, safety of DU-176b 30mg or DU-176b 15mg versus enoxaparin sodium for the prevention of venous thromboembolism in patients after elective total hip arthroplasty.
- Conditions
- Venous Thromboembolism, Thromboembolism, Thrombosis, Embolism and Thrombosis
- Trial name
- NCT01203098
- Testing
- DU-176b 15mg, DU-176b 30mg, Enoxaparin sodium 20 mg (=2000IU)
- Where
- 3 sites in Japan, Taiwan
- Volunteers
- 264 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Acute DVT of Lower Extremity
Vascular Boot Warming Program After Acute Deep Vein Thrombosis (DVT) ± Pulmonary Embolism (PE)
The Researchers are studying whether a vascular boot warming program plus standard of care anticoagulation can be a safe and effective method to resolve Deep Vein Thrombosis (DVT) ±Pulmonary Embolism (PE) earlier and prevent…
- Trial name
- NCT03465735
- Testing
- Vascular Boot, Standard of Care
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Mayo Clinic
Prophylaxis of Venous Thromboembolism
Rivaroxaban in Bariatric Surgery
Until now there ist no systematic investigation of the pharmacokinetic parameters of Rivaroxaban in obese patient undergoing bariatric surgery.
- Trial name
- NCT02438098
- Testing
- Rivaroxaban 10 mg
- Where
- Switzerland
- Volunteers
- 13 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Venous Thromboembolism
Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients
This study will evaluate if extended therapy with oral rivaroxaban can prevent blood clots in the leg and lung that can occur with patients hospitalized for acute medical illness, and compare these results with those of the…
- Trial name
- MAGELLAN (NCT00571649)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Enoxaparin
- Where
- 676 sites in United States, Argentina and 51 more
- Volunteers
- 8,101 people
- Sponsor
- Bayer
Multiple Myeloma, Venous Thromboembolism
Validation of the 4TS RAM in the Prevention of Venous Thromboembolism in Patients With Plasma Cell Dyscrasias.
Patients with newly diagnosed symptomatic multiple myeloma per IMWG criteria prior to therapy initiation are enrolled in the study.
- Trial name
- ROADMAP-MM (NCT03405571)
- Testing
- No intervention
- Where
- Greece
- Volunteers
- 800 people
- Sponsor
- University of Athens